Massachusetts, USA-based Aileron Therapeutics, a biotechnology company discovering and developing a novel class of therapeutics called stapled peptides, says it has closed a $40.0-million series D financing. This was co-led by new investors SR One, the independent corporate venture fund of UK drug giant GlaxoSmithKline, and Excel Medical Fund. The round also included major participation by existing investors: Apple Tree Partners, who is the founding investor of Aileron, and Novartis Venture Fund. Lilly Ventures and Roche Venture Fund also participated in the offering.
Proceeds will be used to advance Aileron's lead stapled peptide program toward clinical trials in 2010 and to further advance this platform and programs in oncology, immune/ inflammation, metabolic disease, and infectious disease. These peptides are synthetically locked, or "stapled," into an alpha-helical shape to create drug compounds that are uniquely effective for targets that are "undruggable" with currently available drug approaches.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze